Home » Stocks » KALV

KalVista Pharmaceuticals, Inc. (KALV)

Stock Price: $25.10 USD 0.29 (1.17%)
Updated May 13, 2021 3:42 PM EDT - Market open
Market Cap 615.00M
Revenue (ttm) 3.82M
Net Income (ttm) -37.87M
Shares Out 17.96M
EPS (ttm) -2.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $25.10
Previous Close $24.81
Change ($) 0.29
Change (%) 1.17%
Day's Open 24.83
Day's Range 24.11 - 25.48
Day's Volume 115,742
52-Week Range 9.32 - 45.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializatio...

3 days ago - Business Wire

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializatio...

1 week ago - Business Wire

CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma space Tuesday. CRISPR Ri...

Other stocks mentioned: SNDX, CRSP
3 weeks ago - Benzinga

Two months after KalVista Pharmaceuticals Inc (NASDAQ: KALV) reported positive Phase 2 results for its lead drug KVD900, an oral therapy meant to stem the effects of swelling attacks caused by the rare ...

3 weeks ago - Benzinga

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializatio...

3 weeks ago - Business Wire

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...

1 month ago - Business Wire

KalVista Pharmaceuticals, Inc. (KALV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

KalVista Pharmaceuticals, Inc. (KALV) delivered earnings and revenue surprises of 6.67% and -100.00%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for t...

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...

2 months ago - Business Wire

KalVista Pharmaceuticals, Inc. (KALV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...

2 months ago - Business Wire

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,2...

2 months ago - Business Wire

KalVista Pharmaceuticals Inc (NASDAQ: KALV) prices its upsized underwritten public offering of 5.375 million at $36 per share, raising $193.5 million in gross proceeds. Earlier, the company offered 4.5 ...

3 months ago - Benzinga

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 share...

3 months ago - Business Wire

Can this under-the-radar biotech and its hereditary angioedema candidate produce more gains for investors?

3 months ago - The Motley Fool

Analysts say the biotech's investors could be in store for even more gains.

3 months ago - The Motley Fool

Do favorable results in a mid-stage drug trial justify the stock of the developer more than doubling in a day?

3 months ago - GuruFocus

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) announced today that it intends to offer and sell 4,500,000 shares of its common stock in an underwritten publi...

3 months ago - Business Wire

Shares of KALV stock are blasting off on Tuesday after KalVista Pharmaceuticals reported strong results from its HAE treatment clinical trial. The post KALV Stock: 8 Things to Know About KalVista Pharma...

3 months ago - InvestorPlace

Shares of Kalvista Pharmaceuticals Inc (NASDAQ: KALV) are sharply higher Tuesday following the release of a mid-Phase clinical readout. What Happened: Kalvista, which focuses on developing small molecul...

3 months ago - Benzinga

Kalvista Pharmaceuticals Inc's (NASDAQ: KALV) oral plasma kallikrein inhibitor, KVD900, has reduced the use of rescue medication in patients suffering swelling attacks associated with hereditary angioed...

3 months ago - Benzinga

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...

3 months ago - Business Wire

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experien...

Other stocks mentioned: ASND
3 months ago - Business Wire

Investors need to pay close attention to KalVista Pharmaceuticals (KALV) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

KalVista Pharmaceuticals (KALV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...

5 months ago - Business Wire

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...

6 months ago - Business Wire

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commerc...

6 months ago - Business Wire

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc.

7 months ago - Business Wire

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc.

8 months ago - Business Wire

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc.

9 months ago - Business Wire

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...

10 months ago - Business Wire

Sell-side analysts on Wall Street recommend to buy shares of Stemline Therapeutics Inc (NASDAQ:STML) and KalVista Pharmaceuticals Inc (NASDAQ:KALV), even though their share prices have lost more than 59...

Other stocks mentioned: STML
1 year ago - GuruFocus

Sell-side analysts on Wall Street recommend to buy shares of Stemline Therapeutics Inc (NASDAQ:STML) and KalVista Pharmaceuticals Inc (NASDAQ:KALV), even though their share prices have lost more than 59...

Other stocks mentioned: STML
1 year ago - GuruFocus

Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.

Other stocks mentioned: DVA, ENSG, MEIP, RMD
1 year ago - Zacks Investment Research

Here are five defensive stocks that can shield your portfolio from China's coronavirus that intimidates to weigh on the stock market.

Other stocks mentioned: CDNA, CVGW, DAR, SMPL
1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals.

1 year ago - Zacks Investment Research

Prospects Appear Bright for Small Drug Industry in 2020

Other stocks mentioned: AMRX, COLL, MTNB
1 year ago - Zacks Investment Research

Shares of thinly-traded micro-cap biotech Kalvista Pharmaceuticals Inc (NASDAQ: KALV) are seen moving to the downside Monday.

1 year ago - Benzinga

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals, Inc. (KALV).

1 year ago - Zacks Investment Research

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

These are five stocks to consider buying because of significant insider buying activity. Insiders only buy for one reason: to make money.

Other stocks mentioned: FDX, HRTX, IMMU, VBIV
1 year ago - InvestorPlace

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

KALV is an early stage company without much efficacy data, but early data for its drug candidates are promising.

1 year ago - Seeking Alpha

Clinical-stage biopharma KalVista Pharmaceuticals has lost approximately 40% of its value since early April as it entered a news vacuum.

1 year ago - Seeking Alpha

KalVista's valuation continues to drift but it has two things going for it: cash runway & catalysts.

1 year ago - Seeking Alpha

KalVista Pharmaceuticals, Inc. (KALV) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

1 year ago - Zacks Investment Research

Shares of KalVista have fallen nearly 30% this month due to sector weakness and insider sales (presumably).

1 year ago - Seeking Alpha

KalVista Pharmaceuticals (KALV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

About KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for ... [Read more...]

Industry
Biotechnology
CEO
Thomas Crockett
Employees
56
Stock Exchange
NASDAQ
Ticker Symbol
KALV
Full Company Profile

Financial Performance

In 2020, KALV's revenue was $12.69 million, a decrease of -21.31% compared to the previous year's $16.13 million. Losses were -$29.12 million, 39.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for KALV stock is "Strong Buy." The 12-month stock price forecast is 55.43, which is an increase of 120.84% from the latest price.

Price Target
$55.43
(120.84% upside)
Analyst Consensus: Strong Buy